<div id="readability-page-1"><p>Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) has been assigned a consensus recommendation of &#34;Hold&#34; from the eight analysts that are currently  covering the company, Marketbeat Ratings reports. One investment analyst  has rated the stock with a sell recommendation, three have assigned  a hold recommendation and four have issued  a buy recommendation on  the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.30.</p><div><p><span></span><span>Get <strong>Sight Sciences</strong> alerts:</span></p></div><p>Several brokerages have issued reports on SGHT. UBS Group lifted their price target on shares of Sight Sciences from $7.00 to $12.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, December 23rd. Citigroup lifted their target price on Sight Sciences from $5.50 to $9.10 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, December 11th. Weiss Ratings  reissued a &#34;sell (e+)&#34; rating on shares of Sight Sciences in a research report on Monday, December 29th. Morgan Stanley boosted their price target on Sight Sciences from $6.00 to $8.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Tuesday, December 2nd. Finally, Lake Street Capital upped their price objective on Sight Sciences from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, October 21st.</p><p><b>Read Our Latest Report on Sight Sciences</b></p><h2>Insider Buying and Selling</h2><p>In other news, EVP Brenton Taylor sold 14,418 shares of the business's stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $7.06, for a total transaction of $101,791.08. Following the transaction, the executive vice president directly owned 170,831 shares in the company, valued at $1,206,066.86. The trade was a 7.78% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CFO James Rodberg sold 4,405 shares of the firm's stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10. Following the completion of the sale, the chief financial officer owned 154,440 shares of the company's stock, valued at $1,207,720.80. This trade represents a 2.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 126,092 shares of company stock worth $970,005. Corporate insiders own  30.90% of the company's stock. </p><h2>Institutional Investors Weigh In On Sight Sciences</h2><p>Large investors have recently added to or reduced their stakes in the business. KCK LTD. bought a new position in  Sight Sciences during the second quarter worth $18,069,000.  Long Focus Capital Management LLC lifted its stake in shares of  Sight Sciences by 1.3% during the 3rd quarter. Long Focus Capital Management LLC now owns 3,193,305 shares of the company's stock worth $10,985,000 after buying an additional 41,797 shares during the last quarter.  Vanguard Group Inc. grew its stake in  Sight Sciences by 5.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock valued at $6,559,000 after buying an additional 102,609 shares during the last quarter.  Americana Partners LLC grew its stake in  Sight Sciences by 42.4% in the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company's stock valued at $4,231,000 after buying an additional 365,901 shares during the last quarter.  Finally, B Group Inc. raised its holdings in  Sight Sciences by 11.6% in the 2nd quarter. B Group Inc. now owns 930,000 shares of the company's stock valued at $3,841,000 after acquiring an additional 96,400 shares during the period. Institutional investors own  55.51% of the company's stock. </p><h2>Sight Sciences Stock Down 4.6%</h2><p>NASDAQ:SGHT opened at $7.18 on Friday. The stock has a 50-day simple moving average of $7.66 and a 200 day simple moving average of $5.19. Sight Sciences has a 52-week low of $2.03 and a 52-week high of $9.24. The company has a market cap of $379.61 million, a PE ratio of -7.98 and a beta of 2.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 8.93 and a current ratio of 9.60. </p><p>Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings results on Wednesday, September 8th. The company reported ($0.81) earnings per share for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The business had revenue of $12.54 million for the quarter.  On average, sell-side analysts expect that  Sight Sciences will post -0.99 EPS for the current fiscal year. </p><h2>Sight Sciences Company Profile</h2> (Get Free Report)<p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.  </p><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Sight Sciences</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Do not delete, read immediately</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2><p>Before you consider Sight Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SGHT

<p>Sight Sciences, Inc. (NASDAQ:SGHT) has received a consensus rating of "Hold" from eight analysts. The average price target is $8.30, with one sell, three hold, and four buy recommendations. Recent price targets include UBS raising it to $12.00 and Citigroup to $9.10. Insider selling includes EVP Brenton Taylor and CFO James Rodberg. Institutional investors own 55.51% of the stock. The stock is currently down 4.6%, trading at $7.18, with a market cap of $379.61 million and a PE ratio of -7.98. The company reported a loss of $0.81 per share last quarter.</p>

Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Rating of "Hold" by Brokerages